Global Lung Cancer Therapeutics
Market Report
2025
Lung Cancer Therapeutics Market Report 2025 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
|
Rating: 4.8 | Review: 12
Share your contact details to receive free updated sample copy/pages of the recently published edition of Lung Cancer Therapeutics Market Report 2024.
Global Lung Cancer Therapeutics Market Report 2024 Market Size Split by Disease Type (Non-small cell lung cancer, Small cell lung cancer), by Treatment (Surgery, Chemotherapy, Radiation therapy, Immun...
According to cognitive market research, the global lung cancer therapeutics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.
- The lungs are two spongy organs in the chest that control breathing. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer. The risk of lung cancer increases with the length of time and number of cigarettes smoked.
- The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals
- The chemotherapy segment dominated the lung cancer therapeutics market revenue in 2024 and is projected to be the fastest-growing segment during the forecast period. Chemotherapy goes throughout the entire body for tumor cells, whereas radiation and surgery target a single region of the body.
- Moreover, this market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines.
- There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the instruments adds up to the total cost.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Disease Type |
|
| Market Split by Treatment |
|
| Market Split by End-User |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Report scope is customizable as we have a huge database of Lung Cancer Therapeutics industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Lung Cancer Therapeutics Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Lung Cancer Therapeutics Market Report Description
Introduction of the Lung Cancer Therapeutics
Lung cancer is a kind of cancer that starts as a growth of cells in the lungs. The lungs are two spongy organs in the chest that control breathing. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer. The risk of lung cancer increases with the length of time and number of cigarettes smoked. Quitting smoking, even after smoking for many years, significantly lowers the chances of developing lung cancer. Lung cancer also can happen in people who have never smoked.
Factors driving the market growth include the increasing prevalence of lung cancer, rising pollution due to rapid industrialization, growth in the number of smokers, and increasing funding for the R&D of new drugs. The lung cancer therapeutics market is moderately concentrated in nature due to the presence of companies operating globally as well as regionally. For the inhalation treatment of lung cancer, a wide range of nanocarriers have been studied, including liposomes, micelles, polymeric NPs, inorganic NPs, and solid lipid NPs. Different medication classes combat cancer cells in different ways. A personalized treatment strategy will be suggested by the oncologist for each patient.
Lung Cancer Therapeutics Market Size
Market Dynamics of the Lung Cancer Therapeutics
Key Drivers of the Lung Cancer Therapeutics
- The strong prevalence of lung cancer is notably driving market growth.
One of the most prevalent forms of cancer is lung cancer. Several reasons, including the aging population and lifestyle changes, have contributed to a notable increase in the number of new instances of cancer, particularly lung cancer, in recent years. In the United States, 6.2% of the population is at risk of developing lung cancer. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals.
• For instance, according to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of color at 20%. Hence, the increasing prevalence of cancer and the need for effective treatment is likely to contribute to market growth.
(Source:https://www.lung.org/research/state-of-lung-cancer/key-findings)
- Rising pollution due to rapid industrialization increases the incidences of lung cancer
Air pollution (outdoor and indoor particulate matter and ozone) is closely linked to the rising prevalence of heart disease and strokes, lung cancer, lower respiratory infections, diabetes, and chronic obstructive pulmonary disease (COPD). The Global Burden of Disease Study Report (2019) ranks air pollution as the third leading cause of death worldwide. Globally, air pollution is responsible for 6.82 million deaths annually, of which 33% are caused by interior pollution and 66% by outdoor pollution.
• For instance, According to the conference organized by the Associated Chambers of Commerce and Industry of India (ASSOCHAM), ‘Lung Cancer- Awareness, Prevention, Challenges & Treatment’, air pollution is the leading cause of the rise of lung cancer in the country. Around 63 out of the 100 most polluted places on earth belong to India.
(Source:https://www.assocham.org/press-release-page.php?release-name=air-pollution-is-the-major-cause-of-lung-cancer-in-india-say-health-experts)
Restraints of the Lung Cancer Therapeutics
- Regional disparities in treatment will hamper the market for lung cancer therapeutics
Lung cancer is the most prevalent cause of cancer-related deaths globally, and its impact is particularly felt in lower- and middle-income countries (LMICs), where access to early and effective diagnosis and treatment is often restricted. WHO data show that whereas 90% of cancer patients in high-income countries have access to therapy, only roughly 30% of cancer patients in low-income countries do. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the instruments adds up to the total cost. By 2050, about two-thirds of all people over 60 will live in low- and middle-income countries.
• For instance, The total cost of cancer to the global economy will reach 25.2 trillion international dollars between 2020 and 2050, according to an analysis of 29 cancers across 204 countries. Of that, five types of cancer will account for roughly half of that cost, including lung cancer.
(Source:https://www.advisory.com/daily-briefing/2023/03/09/cancer-costs)
How Did COVID-19 Impact The Lung Cancer Therapeutics Market
The COVID-19 pandemic still poses a threat to the world, particularly to those who already have lung illnesses. Lung cancer patients have faced numerous challenges as a result of the pandemic. About 95 out of 161 patients at the Fifth Affiliated Hospital of Sun Yat-sen University had postponed their return visit by April 2020, and 47 cases were ultimately identified as having delayed entry during the pandemic and needing to stop or postpone their normal anticancer therapy. As COVID-19 targets patients with advanced lung cancer, hospitals figure out how to be extremely meticulous. However, due to the declining number of COVID-19 instances, patients with lung cancer may expect their therapy approach to expand. Many cancer patients have experienced changes in their lung cancer treatment plans. COVID-19 reduced the number of lung cancer patients receiving cancer treatment.
• For instance, a New study published by npj vaccines, shows bivalent COVID-19 booster increases antibody response in lung cancer patients, BA.5 bivalent booster dose enhanced neutralization of Omicron XBB (sub)variants in non-small cell lung cancer (NSCLC) patients.
(Source:https://www.news-medical.net/news/20231123/New-study-shows-bivalent-COVID-19-booster-increases-antibody-response-in-lung-cancer-patients.aspx)
Opportunities of the Lung Cancer Therapeutics
- The arrival of nanomedicine to treat lung cancer
According to research, inhalation chemotherapy based on nanotechnology is more effective than traditional chemotherapy and has fewer adverse effects. For the inhalation treatment of lung cancer, a wide range of nanocarriers have been studied, including liposomes, micelles, polymeric NPs, inorganic NPs, and solid lipid NPs. Smart nanoparticles and a unique surgical method are used in a recently disclosed, efficacious, and promising lung cancer therapeutic strategy that targets lung tumors (Advanced Therapeutics). The previous systems and therapies had certain technological limitations. The advanced lung cancer therapeutics instruments and systems help in removing the cancer cells effectively.
• For instance, The Tata Institute in Mumbai has developed a tablet that could prevent cancer from recurring and reduce the side effects of treatment by 50%. The tablet, which will cost just ?100, is awaiting approval from the Food Safety and Standards Authority of India (FSSAI) and could be available in the market by June 2024.
We have various report editions of Lung Cancer Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: Lung Cancer Therapeutics Market
By expanding their market presence and attracting new customers, the industry's players focus on leveraging the present business opportunities in the lung cancer therapeutics market. Market participants are bringing new products to the market. Eli Lilly and Company, Hoffmann-La Roche, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG. and other significant players are among the important participants. Smart nanoparticles and a unique surgical method are used in a recently disclosed, efficacious, and promising lung cancer therapeutic strategy that targets lung tumors (Advanced Therapeutics). Additionally, they are establishing partnerships, manufacturing facilities, and distribution networks to meet the expanding need for electric vehicles across a range of geographic areas.
Top Companies Market Share in Lung Cancer Therapeutics Industry: (In no particular order of Rank)
- Pfizer
- Roche
- Merck
- AstraZeneca
- Sanofi-Aventis
- Eli Lilly and Company
- Abbott
- Akebia Therapeutics
- Agennix AG
- Allergan Inc.
- Teva Pharmaceutical Industries Ltd.
- Abbvie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Which Region will dominate the Market in 2024?
North America was the leading lung cancer therapeutics market in 2021 and it is expected to remain dominant throughout the forecast period. The rising prevalence of lung cancer and the growing adoption of advanced diagnosis and lung cancer therapeutics for the treatment of lung cancer has resulted in the increased demand for lung cancer therapeutics in this region. The UK dominates the European lung cancer therapeutics market due to the rise in no of patients suffering from lung cancer in this region. Furthermore, better access to expensive and sophisticated therapies has been made possible by North America's rising health insurance penetration rate. Additionally, the region's robust and established healthcare infrastructure as well as easier access to cutting-edge medical facilities have greatly aided in the market's expansion.
Which Region is Expanding at the Fastest CAGR?
Asia Pacific is estimated to exhibit the highest CAGR during the forecast period. The rising prevalence of smoking and exposure to secondhand smoke is resulting in the growing prevalence of lung cancer among the population. Rising investments of the top biopharmaceutical companies in the Asia-Pacific region to expand their manufacturing facilities and produce advanced drugs at low cost are significantly driving the growth of the market. India's cancer care infrastructure remains inadequate about the population and load of cancer patients. Failure to overcome these shortcomings may result in higher mortality rates and shorter survival rates for cancer patients in India when compared to developed countries. In India, the CDSCO oversees enforcing and authorizing lung cancer medicines.
The current report Scope analyzes Lung Cancer Therapeutics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Lung Cancer Therapeutics Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Lung Cancer Therapeutics Market Analysis
Global Lung Cancer Therapeutics Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Lung Cancer Therapeutics Industry growth. Lung Cancer Therapeutics market has been segmented with the help of its Disease Type, Treatment End-User, and others. Lung Cancer Therapeutics market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Lung Cancer Therapeutics Disease Type Segment Analysis
- Non-small cell lung cancer
- Small cell lung cancer
Based on the disease type lung cancer therapeutics market is divided into non-small cell lung cancer and small cell lung cancer. The non-stem cell lung cancer segment dominated the market growth in 2024 and is projected to be the fastest-growing segment during the forecast period, 2024-2031. Because non-small cell lung cancer (NSCLC) begins at the cellular level, lung cancer cells proliferate quickly and unpredictably. It is more common in women and typically develops in the outer part of the lungs. After the diagnosis of NSCLC, the stage of cancer is determined. Approximately 90% of cases of non-small cell lung cancer are caused by smoking. Patients with NSCLC have a 5-year survival rate of 63%. To treat NSCLC, patients may combine radiation therapy, chemotherapy, surgery, and targeted therapy. The most prevalent kind of lung cancer, accounting for around 80% of all lung malignancies, is non-small cell lung cancer.
• For instance, in May 2021, Janssen Pharmaceutical reported that the U.S. FDA granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Such product approvals are also adding to the growth of the market and are likely to do the same over the forecast period.
(Source:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications)
• For instance, in October 2021, United States FDA approved the immunotherapy drug atezlizumab (Tecentriq) as an additional treatment after surgery and chemotherapy for some patients with non-small cell lung cancer (NSCLC). The recent approval of drugs for the treatment of non-small cell lung cancer is likely to boost the growth of the market.
(Source:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer)
Lung Cancer Therapeutics Market Share (%) by Disease Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Lung Cancer Therapeutics Industry. Request a Free Sample PDF!
Lung Cancer Therapeutics Treatment Segment Analysis
- Surgery
- Chemotherapy
- Radiation therapy
- Immunotherapy
- Targeted therapy
The market segment of lung cancer therapeutics, based on treatment is divided into surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The chemotherapy segment dominated the lung cancer therapeutics market revenue in 2024 and is projected to be the fastest-growing segment during the forecast period. Chemotherapy goes throughout the entire body for tumor cells, whereas radiation and surgery target a single region of the body. Most of the time, chemotherapy is administered by IV infusion. Chemotherapy functions by obstructing the growth or proliferative potential of cancer cells. Different medication classes combat cancer cells in different ways. A personalized treatment strategy will be suggested by the oncologist for each patient. Chemotherapy for lung cancer can be administered alone, in combination with other treatments, or before other treatments.
• For instance, To improve the odds for patients with lung cancer, researchers from The University of Texas at Arlington and UT Southwestern Medical Center have pioneered a novel approach in chemotherapy to deliver cancer-killing drugs directly into cancer cells, By delivering chemotherapy directly to the tumor cells, the system aims to minimize collateral damage to healthy tissues.
(Source:https://www.uta.edu/news/news-releases/2024/02/23/innovative-chemotherapy-approach-shows-promise-against-lung-cancer)
Lung Cancer Therapeutics Market Share (%) by Treatment in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Lung Cancer Therapeutics End-User Segment Analysis
The lung cancer therapeutics market has been segmented by end-users into Hospitals, clinics, cancer research centers, and laboratories. The hospitals and clinics segment dominated the market in 2024 and is projected to be the fastest-growing segment during the forecast period. sales of lung cancer therapeutics from hospital pharmacies around the world have increased significantly due to the rising no of cancer patients admitted to hospitals for treatment and diagnosis. Moreover, this market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines
- Hospitals
- Clinics
- Cancer Research Centers
- Laboratories
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Bio :
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. Market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals.
Frequently Asked Questions
Lung Cancer Therapeuticsmarket size and its growth rate has been provided in the report. The historical period included in the report is from 2019 to 2023, whereas, the report provides forecast data for the years 2024 to 2031. This will help you to in terms of global market share, regional market share, country level market share to understand how the market has been performing in the past and how it is going to perform in the following years. Correspondingly, historical and forecast analysis comprises sales and revenue data of the global Lung Cancer Therapeuticsmarket. Market size for UK, Europe, North America, Asia Pacific, Middle East & Africa is also included in the report.
The major factors affecting the Lung Cancer Therapeutics market in a positive, as well as negative perspective, have been provided with detailed analysis in the report. This segment has encompassed drivers, opportunities, and challenges faced by the industry. This will help you to understand the major factors impacting Lung Cancer Therapeutics market trends and develop your business strategy accordingly.
Major manufacturers or list of Lung Cancer Therapeutics manufacturers 2024 involved in the market have been profiled in the report along with their business strategies, recent developments, SWOT analysis, business overview, and market Trend from the year 2019-2023. Lung Cancer Therapeutics Companies such as Pfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie Inc., Johnson & Johnson, Amgen Inc., Novartis AG are part of the final deliverable document along with the same we can provide data for 2nd, 3rd, start-up level companies data and strategies as well. This will help you to understand the competitive analysis of the market and how other players are performing in the market. This detailed competitive analysis will help you to strategize your business accordingly and will keep you one step ahead. A quantitative and qualitative analysis of the main players in the Lung Cancer Therapeutics market is introduced, from the perspective of sales, revenue and price.
Under Lung Cancer Therapeutics market segments analysis Disease Type, Treatment, End-User. It provides detailed insights on each type and application. Further, it provides which sub-segment is dominating the Lung Cancer Therapeutics market along with its reason. Additionally, the Lung Cancer Therapeutics market report will help you to analyze which sub-segment is fastest-growing during the forecast period.
After the analysis of the complete market, the report has provided how the COVID-19 pandemic has affected the market. All the parameters have covered the overall impact of COVID -19 on the market value, market trend & growth of the market, and how the major players in the particular market are adopting these changes. This will help you to understand the overall optimistic, pessimistic, and neutral effects of the coronavirus pandemic on the Lung Cancer Therapeutics market.
The Lung Cancer Therapeutics market has been analyzed thoroughly and has estimated the parameters which have affected the market in the historical period as well as how the market is going to perform in the following years. This will provide a complete market scenario and help you to strategize your next move accordingly to the Lung Cancer Therapeutics market Share.
The report gives an exhaustive investigation of the Lung Cancer Therapeutics market at country & regional levels, and provides an analysis of the industry trends in each of the regions, from sales, revenue, and consumption. It will help you to understand which region is dominating the market and is expected to grow significantly in the following years. The regional analysis will help you in strategizing the expansion of business.
Lung Cancer Therapeuticsmarket report has provided PESTEL and Porter analysis to provide insightful information regarding the market scenario. It also provides market attractiveness analysis with an acknowledgment of various factors within the market, including growth rate and market size, as well as outside factors such as access to raw materials, competition, and industry capacity.
The sample report for the Lung Cancer Therapeutics Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Lung Cancer Therapeutics Market
AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) along with pemetrexed and platinum-based chemotherapy, to treat epidermal growth factor receptor (EGFR)-mutated lung cancer.
The approval is meant to be used as a first-line therapy for individuals with certain EGFR mutations who have locally progressed or metastatic non-small cell lung cancer (NSCLC). The FLAURA2 Phase III clinical study, which showed a 38% decrease in the risk of disease progression or mortality when Tagrisso was paired with chemotherapy as opposed to Tagrisso monotherapy, is the basis for Health Canada's decision. Five hundred fifty-seven patients from 150 centers in 20 countries—three in Canada—were enrolled in the open-label, randomized, multicenter, international trial. Patients receiving combination treatment had a median progression-free survival (PFS) of 25.5 months, which was 8.8 months longer than that of Tagrisso monotherapy patients at 16.7 months.
Source Link: https://www.pharmaceutical-technology.com/news/astra-zeneca-tagrisso-canada-nsclc/#:~:text=AstraZeneca's%20Tagrisso%20gains%20approval%20in,the%20risk%20of%20disease%20progression.&text=The%20approval%20is%20for%20the,NSCLC%20with%20specific%20EGFR%20mutations.
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Lung Cancer Therapeutics Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Disease Type | Non-small cell lung cancer, Small cell lung cancer |
| Treatment | Surgery, Chemotherapy, Radiation therapy, Immunotherapy, Targeted therapy |
| End-User | Hospitals, Clinics, Cancer Research Centers, Laboratories |
| List of Competitors | Pfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie Inc., Johnson & Johnson, Amgen Inc., Novartis AG |
Expand All
This chapter will help you gain GLOBAL Market Analysis of Lung Cancer Therapeutics. Further deep in this chapter, you will be able to review Global Lung Cancer Therapeutics Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Lung Cancer Therapeutics Revenue Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Lung Cancer Therapeutics Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Lung Cancer Therapeutics Revenue Market Size By Region
-
-
1.3 Global Lung Cancer Therapeutics Market Size By Disease Type 2019 -2031
-
1.3.1 Non-small cell lung cancer Market Size
-
1.3.2 Small cell lung cancer Market Size
-
-
1.4 Global Lung Cancer Therapeutics Market Size By Treatment 2019 -2031
-
1.4.1 Surgery Market Size
-
1.4.2 Chemotherapy Market Size
-
1.4.3 Radiation therapy Market Size
-
1.4.4 Immunotherapy Market Size
-
1.4.5 Targeted therapy Market Size
-
-
1.5 Global Lung Cancer Therapeutics Market Size By End-User 2019 -2031
-
1.5.1 Hospitals Market Size
-
1.5.2 Clinics Market Size
-
1.5.3 Cancer Research Centers Market Size
-
1.5.4 Laboratories Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Disease Type
-
1.7.3 Global Market Revenue Split By Treatment
-
1.7.4 Global Market Revenue Split By End-User
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
This chapter will help you gain North America Market Analysis of Lung Cancer Therapeutics. Further deep in this chapter, you will be able to review North America Lung Cancer Therapeutics Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
-
2.1 North America Lung Cancer Therapeutics Market Size 2019 - 2031
-
2.1.1 North America Lung Cancer Therapeutics Market Size By Country 2019 - 2031
-
2.1.2 North America Lung Cancer Therapeutics Market Size by Disease Type 2019 -2031
-
2.1.2.1 North America Non-small cell lung cancer Market Size
-
2.1.2.2 North America Small cell lung cancer Market Size
-
-
2.1.3 North America Lung Cancer Therapeutics Market Size by Treatment 2019 -2031
-
2.1.3.1 North America Surgery Market Size
-
2.1.3.2 North America Chemotherapy Market Size
-
2.1.3.3 North America Radiation therapy Market Size
-
2.1.3.4 North America Immunotherapy Market Size
-
2.1.3.5 North America Targeted therapy Market Size
-
-
2.1.4 North America Lung Cancer Therapeutics Market Size by End-User 2019 -2031
-
2.1.4.1 North America Hospitals Market Size
-
2.1.4.2 North America Clinics Market Size
-
2.1.4.3 North America Cancer Research Centers Market Size
-
2.1.4.4 North America Laboratories Market Size
-
-
This chapter will help you gain Europe Market Analysis of Lung Cancer Therapeutics. Further deep in this chapter, you will be able to review Europe Lung Cancer Therapeutics Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
-
3.1 Europe Lung Cancer Therapeutics Market Size 2019 - 2031
-
3.1.1 Europe Lung Cancer Therapeutics Market Size By Country 2019 - 2031
-
3.1.2 Europe Lung Cancer Therapeutics Market Size by Disease Type 2019 -2031
-
3.1.2.1 Europe Non-small cell lung cancer Market Size
-
3.1.2.2 Europe Small cell lung cancer Market Size
-
-
3.1.3 Europe Lung Cancer Therapeutics Market Size by Treatment 2019 -2031
-
3.1.3.1 Europe Surgery Market Size
-
3.1.3.2 Europe Chemotherapy Market Size
-
3.1.3.3 Europe Radiation therapy Market Size
-
3.1.3.4 Europe Immunotherapy Market Size
-
3.1.3.5 Europe Targeted therapy Market Size
-
-
3.1.4 Europe Lung Cancer Therapeutics Market Size by End-User 2019 -2031
-
3.1.4.1 Europe Hospitals Market Size
-
3.1.4.2 Europe Clinics Market Size
-
3.1.4.3 Europe Cancer Research Centers Market Size
-
3.1.4.4 Europe Laboratories Market Size
-
-
This chapter will help you gain Asia Pacific Market Analysis of Lung Cancer Therapeutics. Further deep in this chapter, you will be able to review Asia Pacific Lung Cancer Therapeutics Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Lung Cancer Therapeutics Market Size 2019 - 2031
-
4.1.1 Asia Pacific Lung Cancer Therapeutics Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Lung Cancer Therapeutics Market Size by Disease Type 2019 -2031
-
4.1.2.1 Asia Pacific Non-small cell lung cancer Market Size
-
4.1.2.2 Asia Pacific Small cell lung cancer Market Size
-
-
4.1.3 Asia Pacific Lung Cancer Therapeutics Market Size by Treatment 2019 -2031
-
4.1.3.1 Asia Pacific Surgery Market Size
-
4.1.3.2 Asia Pacific Chemotherapy Market Size
-
4.1.3.3 Asia Pacific Radiation therapy Market Size
-
4.1.3.4 Asia Pacific Immunotherapy Market Size
-
4.1.3.5 Asia Pacific Targeted therapy Market Size
-
-
4.1.4 Asia Pacific Lung Cancer Therapeutics Market Size by End-User 2019 -2031
-
4.1.4.1 Asia Pacific Hospitals Market Size
-
4.1.4.2 Asia Pacific Clinics Market Size
-
4.1.4.3 Asia Pacific Cancer Research Centers Market Size
-
4.1.4.4 Asia Pacific Laboratories Market Size
-
-
This chapter will help you gain South America Market Analysis of Lung Cancer Therapeutics. Further deep in this chapter, you will be able to review South America Lung Cancer Therapeutics Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
-
5.1 South America Lung Cancer Therapeutics Market Size 2019 - 2031
-
5.1.1 South America Lung Cancer Therapeutics Market Size By Country 2019 - 2031
-
5.1.2 South America Lung Cancer Therapeutics Market Size by Disease Type 2019 -2031
-
5.1.2.1 South America Non-small cell lung cancer Market Size
-
5.1.2.2 South America Small cell lung cancer Market Size
-
-
5.1.3 South America Lung Cancer Therapeutics Market Size by Treatment 2019 -2031
-
5.1.3.1 South America Surgery Market Size
-
5.1.3.2 South America Chemotherapy Market Size
-
5.1.3.3 South America Radiation therapy Market Size
-
5.1.3.4 South America Immunotherapy Market Size
-
5.1.3.5 South America Targeted therapy Market Size
-
-
5.1.4 South America Lung Cancer Therapeutics Market Size by End-User 2019 -2031
-
5.1.4.1 South America Hospitals Market Size
-
5.1.4.2 South America Clinics Market Size
-
5.1.4.3 South America Cancer Research Centers Market Size
-
5.1.4.4 South America Laboratories Market Size
-
-
This chapter will help you gain Middle East and Africa Market Analysis of Lung Cancer Therapeutics. Further deep in this chapter, you will be able to review Middle East and Africa Lung Cancer Therapeutics Market Split by various segments and Country Split.
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Lung Cancer Therapeutics Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Lung Cancer Therapeutics Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Lung Cancer Therapeutics Market Size by Disease Type 2019 -2031
-
6.1.2.1 Middle East and Africa Non-small cell lung cancer Market Size
-
6.1.2.2 Middle East and Africa Small cell lung cancer Market Size
-
-
6.1.3 Middle East and Africa Lung Cancer Therapeutics Market Size by Treatment 2019 -2031
-
6.1.3.1 Middle East and Africa Surgery Market Size
-
6.1.3.2 Middle East and Africa Chemotherapy Market Size
-
6.1.3.3 Middle East and Africa Radiation therapy Market Size
-
6.1.3.4 Middle East and Africa Immunotherapy Market Size
-
6.1.3.5 Middle East and Africa Targeted therapy Market Size
-
-
6.1.4 Middle East and Africa Lung Cancer Therapeutics Market Size by End-User 2019 -2031
-
6.1.4.1 Middle East and Africa Hospitals Market Size
-
6.1.4.2 Middle East and Africa Clinics Market Size
-
6.1.4.3 Middle East and Africa Cancer Research Centers Market Size
-
6.1.4.4 Middle East and Africa Laboratories Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Lung Cancer Therapeutics Market Size by Disease Type 2019 -2031
-
7.1.2 Country 1Lung Cancer Therapeutics Market Size by Treatment 2019 -2031
-
7.1.3 Country 1Lung Cancer Therapeutics Market Size by End-User 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
This chapter provides an in-depth analysis of the market share among key competitors of Lung Cancer Therapeutics. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Lung Cancer Therapeutics Market Revenue and Share by Key Players
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Pfizer
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Roche
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 Merck
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 AstraZeneca
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Sanofi-Aventis
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Eli Lilly and Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Abbott
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Akebia Therapeutics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Agennix AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Allergan Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Teva Pharmaceutical Industries Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Abbvie Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Johnson & Johnson
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Amgen Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Novartis AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Restraints
-
9.3 Market Trends
-
9.4 Market Opportunity
-
9.5 Technological Road Map (Subject to Data Availability)
-
9.6 Product Life Cycle (Subject to Data Availability)
-
9.7 Consumer Preference Analysis
-
9.8 Market Attractiveness Analysis
-
9.9 PESTEL Analysis
-
9.9.1 Political Factors
-
9.9.2 Economic Factors
-
9.9.3 Social Factors
-
9.9.4 Technological Factors
-
9.9.5 Legal Factors
-
9.9.6 Environmental Factors
-
-
9.10 Industrial Chain Analysis (Subject to Data Availability)
-
9.10.1 Industry Chain Analysis
-
9.10.2 Manufacturing Cost Analysis
-
9.10.3 Supply Side Analysis
-
9.10.3.1 Raw Material Analysis
-
9.10.3.2 Raw Material Procurement Analysis
-
9.10.3.3 Raw Material Price Trend Analysis
-
-
-
9.11 Porter’s Five Forces Analysis
-
9.11.1 Bargaining Power of Suppliers
-
9.11.2 Bargaining Power of Buyers
-
9.11.3 Threat of New Entrants
-
9.11.4 Threat of Substitutes
-
9.11.5 Degree of Competition
-
-
9.12 Patent Analysis (Subject to Data Availability)
-
9.13 ESG Analysis
Segmentation Disease Type Analysis 2019 -2031, will provide market size split by Disease Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Disease Type Analysis 2019 -2031
-
10.1 Non-small cell lung cancer
-
10.1.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Non-small cell lung cancer 2019 -2031
-
-
10.2 Small cell lung cancer
-
10.2.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Small cell lung cancer 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Treatment Analysis 2019 -2031
-
11.1 Surgery
-
11.1.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Surgery 2019 - 2031
-
-
11.2 Chemotherapy
-
11.2.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Chemotherapy 2019 - 2031
-
-
11.3 Radiation therapy
-
11.3.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Radiation therapy 2019 - 2031
-
-
11.4 Immunotherapy
-
11.4.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Immunotherapy 2019 - 2031
-
-
11.5 Targeted therapy
-
11.5.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Targeted therapy 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End-User Analysis 2019 -2031
-
12.1 Hospitals
-
12.1.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Hospitals 2019 -2031
-
-
12.2 Clinics
-
12.2.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Clinics 2019 -2031
-
-
12.3 Cancer Research Centers
-
12.3.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Cancer Research Centers 2019 -2031
-
-
12.4 Laboratories
-
12.4.1 Global Lung Cancer Therapeutics Revenue Market Size and Share by Laboratories 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Lung Cancer Therapeutics market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Lung Cancer Therapeutics Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Lung Cancer Therapeutics Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Lung Cancer Therapeutics Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Lung Cancer Therapeutics Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Lung Cancer Therapeutics Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Lung Cancer Therapeutics Market
Key Questions Answered By Lung Cancer Therapeutics Market Report 2024
| Why Non-small cell lung cancer have a significant impact on Lung Cancer Therapeutics market? |
| What are the key factors affecting the Non-small cell lung cancer and Small cell lung cancer of Lung Cancer Therapeutics Market? |
| What is the CAGR/Growth Rate of Surgery during the forecast period? |
| By type, which segment accounted for largest share of the global Lung Cancer Therapeutics Market? |
| Which region is expected to dominate the global Lung Cancer Therapeutics Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
